Wall Street brokerages expect that Proteostasis Therapeutics Inc (NASDAQ:PTI) will announce earnings of ($0.58) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Proteostasis Therapeutics’ earnings. The highest EPS estimate is ($0.55) and the lowest is ($0.61). Proteostasis Therapeutics posted earnings of ($0.87) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The business is expected to announce its next earnings report on Friday, May 12th.
On average, analysts expect that Proteostasis Therapeutics will report full year earnings of ($2.16) per share for the current financial year, with EPS estimates ranging from ($2.46) to ($1.77). For the next year, analysts forecast that the business will report earnings of ($2.19) per share, with EPS estimates ranging from ($2.53) to ($1.89). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Proteostasis Therapeutics.
Several equities analysts recently commented on PTI shares. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, January 24th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of Proteostasis Therapeutics in a research report on Sunday, April 2nd.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded down 1.77% on Thursday, reaching $6.10. 269,878 shares of the company’s stock traded hands. The company’s market cap is $152.65 million. Proteostasis Therapeutics has a 12-month low of $5.85 and a 12-month high of $20.63. The stock has a 50-day moving average price of $10.25 and a 200-day moving average price of $11.95.
In related news, insider Fmr Llc sold 45,000 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $14.62, for a total value of $657,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 257,300 shares of company stock valued at $3,451,694 over the last ninety days. 29.50% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of PTI. Victory Capital Management Inc. acquired a new position in shares of Proteostasis Therapeutics during the third quarter valued at $307,000. JPMorgan Chase & Co. increased its position in shares of Proteostasis Therapeutics by 174.7% in the third quarter. JPMorgan Chase & Co. now owns 172,650 shares of the company’s stock valued at $2,692,000 after buying an additional 109,800 shares during the period. Monashee Investment Management LLC acquired a new position in shares of Proteostasis Therapeutics during the third quarter valued at $1,325,000. NEA Management Company LLC increased its position in shares of Proteostasis Therapeutics by 14.9% in the third quarter. NEA Management Company LLC now owns 3,556,778 shares of the company’s stock valued at $55,450,000 after buying an additional 461,538 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Proteostasis Therapeutics during the third quarter valued at $395,000. Institutional investors own 67.71% of the company’s stock.
WARNING: “Brokerages Expect Proteostasis Therapeutics Inc (PTI) Will Post Earnings of -$0.58 Per Share” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://transcriptdaily.com/2017/05/20/brokerages-expect-proteostasis-therapeutics-inc-pti-will-post-earnings-of-0-58-per-share-updated-updated-updated.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.